What Kelis Treats: Main Uses and Benefits

Kelis (Ketoprofen) is commonly used to help with symptomatic treatment focused on providing supportive relief from physical manifestations driven by inflammation. Its use is centered on addressing three major domains of patient discomfort, which contributes to easing the overall burden of symptoms and generally supports improved day-to-day comfort. The medication is commonly used to help treat pain, inflammation, swelling, and stiffness associated with various conditions.

---

The therapeutic use of Kelis is considered relevant in conditions presenting with systemic or localized discomfort, applied across domains where additional symptomatic support is needed. It is considered relevant for easing the symptoms of chronic conditions such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis, as well as for managing acute episodes like primary dysmenorrhea, gout flares, and pain from soft tissue injuries or dental procedures.

“The medication is commonly used in scenarios where additional management of discomfort is required due to heightened physiological activity.”

Quick Fact: Relief for Joint Pain and Stiffness

Kelis may assist with managing symptom clusters that become intense or disruptive in both chronic and acute contexts. It is commonly used to help address symptoms related to swelling and tenderness, ease joint stiffness, and manage fever, which may support patients during episodes of heightened discomfort and contribute to maintaining a sense of stability.

Regulatory References

1. MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Kelis (Ketoprofen)

Official regulatory guidelines define strict population eligibility for Kelis, which is based on pre-existing conditions, life stages, and surgical context.

Classification	Population/Condition
Absolute Contraindication	Known hypersensitivity to ketoprofen, aspirin, or other NSAIDs that trigger asthma or urticaria.
Absolute Contraindication	Patients with active peptic ulceration or gastrointestinal haemorrhage.
Absolute Contraindication	Third trimester of pregnancy. Peri-operative pain management following CABG surgery.
Not Recommended	Nursing mothers and women who are attempting to conceive.
Use Not Established	Pediatric population (generally under 18 years) for systemic use. Children under 12 years for topical gel.
Restricted Use/Caution	Elderly patients (requires closer monitoring and potential dose reduction). Patients with uncontrolled hypertension, heart failure, or impaired renal/hepatic function.

Kelis is primarily approved for use in adults. Its regulatory profile strictly excludes individuals with conditions that significantly heighten the risk associated with NSAID use, while placing use under caution for those with organ impairment or advanced age.

The official interaction profile for Kelis (Ketoprofen) focuses on preventing synergistic bleeding risk and drug accumulation, as defined in government regulatory documentation.

Contraindicated and High-Risk Combinations

Co-administration is contraindicated with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including aspirin and COX-2 selective inhibitors, due to an increased risk of serious gastrointestinal (GI) adverse events. The combination of Ketoprofen and Ketorolac is also generally not recommended. Additionally, use in the setting of Coronary Artery Bypass Graft (CABG) surgery is contraindicated.

Pharmacodynamic and Substance Interactions

Certain combinations result in an officially documented additive risk of bleeding. This includes co-administration with anticoagulants (such as Warfarin), antiplatelet agents, corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs). The regulatory documentation also notes that co-administration with alcohol (ethanol) increases the risk of stomach bleeding.

Exposure-Modifying Interactions

Some substances can officially alter drug clearance, resulting in elevated serum levels. Co-administration with Lithium decreases its renal clearance, which elevates plasma lithium concentrations. Similarly, Ketoprofen may cause changes in the elimination of Methotrexate, leading to elevated serum levels of that drug. Probenecid is also noted to reduce Ketoprofen's plasma clearance.

Efficacy and Population Notes

The co-administration of Ketoprofen with Diuretics or ACE-inhibitors may officially diminish the antihypertensive or natriuretic effect of those medications. The regulatory profile notes that elderly patients are at greater risk for serious gastrointestinal adverse events when concomitant use of interacting agents occurs.

Enzyme Inhibition and Prostaglandin Synthesis

Ketoprofen acts as a reversible, non-selective inhibitor of the Cyclooxygenase ( COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. This core action blocks the conversion of arachidonic acid into prostaglandins and related mediators, modifying an early molecular step that shapes subsequent systemic outcomes. By suppressing the key synthesis pathway, the mechanism contributes to altering the signaling dynamics of pro-inflammatory mediators.

️ Dual Modulation of Nociception and Thermoregulation

The resulting reduction in PGE2 concentration exerts a dual action on key regulatory systems. Peripherally, it dampens the chemical signaling that heightens the sensitivity of peripheral nociceptors (nociceptive modulation), while centrally, it adjusts the hypothalamic thermostat to modulate the hypothalamic set point for core body temperature. This process initiates or suppresses signaling sequences that lead to predictable physiological adjustments, influencing the activity patterns within targeted pathways.

How Kelis is Used

Kelis, which contains the active ingredient Ketoprofen, is administered according to specific, officially labeled instructions that govern its route, dosage, and frequency. The primary method for achieving a systemic effect is the Oral route, utilizing immediate-release (IR) or extended-release (ER) capsules. For localized action, the medication is applied topically as a Gel. Other available forms include solutions for injection (parenteral) and suppositories (rectal).

Official Dosing and Administration Schedules

For chronic conditions like rheumatoid arthritis, the systemic daily dosage typically ranges from 150 mg to 300 mg, administered in divided doses when using the IR capsule. The ER capsule is prescribed for once-daily use, not exceeding 200 mg per day. For acute pain and dysmenorrhea, IR capsules are used on an as-needed (PRN) basis at 25 mg to 50 mg every 6 to 8 hours. The total daily intake must not exceed 300 mg for the immediate-release form.

Topical administration involves applying the gel two to four times daily with a gentle massage, generally for a short course of up to seven days, and must not exceed 15 g of gel per day. Oral doses may be taken with food or milk to help manage potential gastrointestinal discomfort. Extended-release capsules must be swallowed whole and must not be chewed or crushed. Official instructions also mandate a lower initial dose for older adults and limit the maximum daily dose to 100 mg for patients with severe renal or hepatic impairment.

Research Evidence / Overview of Studies for Kelis (Ketoprofen)

This section provides a factual overview of the types of official research that have been conducted for Kelis, focusing only on the structure of the studies and the outcomes that were measured, without offering clinical advice or interpretations.

---

1. Evidence for Chronic Inflammatory Conditions

Research exploring the use of Kelis for managing symptoms associated with conditions such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA), has primarily relied on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were used in research exploring how symptoms change over time in patients with conditions characterized by fluctuating or episodic manifestations.

Researchers examined outcomes related to physical discomfort and daily functioning or activity level in adult populations. Examples of measured outcomes include patient-reported changes in pain intensity (often using scales), the duration of morning stiffness, and changes in joint tenderness. Findings describe patterns observed in the studies that were designed to compare Kelis to a placebo or to other similar medicines.

What remains uncertain is the extent of data regarding outcomes over extended periods. While the evidence base for chronic symptom evaluation is significant, the follow-up durations were limited in many of the core comparative RCTs, typically not exceeding a few months. The evidence base focuses purely on monitoring symptom characteristics and not on research exploring the long-term progression of the underlying disease.

---

2. Evidence for Acute Pain Management

Research exploring the use of Kelis for temporary acute pain—such as after a dental procedure or for primary dysmenorrhea—is largely built upon short-term, placebo-controlled RCTs. These trials focus on research exploring short-term symptom changes in conditions associated with acute or disruptive episodes.

In these studies, research examined precise measures related to the speed of symptom change. Outcomes describing episodic or acute changes were monitored, such as the time it took for patients to first report pain relief and how often they required additional pain medication over a fixed, short observation period. The findings describe patterns observed in these studies, where patients reported their pain experience during episodes where symptoms become more noticeable.

Because the focus is on acute episodes, the follow-up durations were limited, sometimes lasting only a single dose or a few days. Therefore, the data for long-term effects are not fully established beyond the immediate post-episode period. Furthermore, comparative evidence is lacking for some of the newer, non-traditional analgesics, meaning studies do not always monitor responses to the latest pharmaceutical options.

---

3. Evidence for Topical (Local) Formulations

Studies exploring the use of Ketoprofen gels or creams for localized soft tissue pain (like sprains or strains) and certain types of localized Osteoarthritis have also utilized controlled trials. These research efforts applied in studies examining patient-reported experiences in conditions marked by functional limitations.

These topical studies compared the medicated gel/cream against a vehicle-only control (the same cream/gel without the active ingredient). The outcomes linked to inflammatory or irritative states were studied, including measurements of pain intensity and local tenderness at the application site. Research highlights changes measured during the study period, often describing patterns in the active group compared to the vehicle-only control group.

---

4. Understanding Long-Term Data and Follow-up

For chronic conditions like arthritis, the most rigorous RCTs typically observe patients for intermediate periods up to three months. This period allows researchers to observe short-term symptom patterns but does not provide extensive data on the durability of observations related to pain and function over the span of several years.

---

5. Research in Specific Patient Groups

Evidence from published studies and regulatory reviews includes information relevant to certain patient groups. Specifically, some data show patterns related to use in older adults. Research has explored patterns related to use in older adults. However, data regarding use in specific populations with concurrent conditions may be limited.

In contrast, evidence for other specific populations, such as children (under 18 years old), is less extensively documented in the core, adult-focused evidence base.

---

6. Synthesis of Research Gaps and Uncertainties

One key research limitation is that comparative evidence is lacking for direct head-to-head assessments against all newer therapeutic options in the modern pain management landscape. Furthermore, although many studies have been conducted, subgroup findings are uncertain, meaning that specific patterns of observation in small groups defined by certain comorbidities are not definitively established. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Systematic review of dexketoprofen in acute and chronic pain (used for acute pain and speed of onset evidence)

Common questions about Kelis (FAQ)

---

Q: How quickly does Kelis start working for acute pain?

Studies and official product information indicate that for the immediate-release form used for acute pain, clinical studies indicated that pain relief, based on patient reports, began within 30 minutes for a percentage of patients after a single dose. This timing is consistent with when the drug typically reaches its peak plasma levels, which occurs approximately 0.5 to 2 hours after administration.

---

Q: How long does Kelis stay in your system?

The time it takes for half of the drug to be eliminated from the plasma, known as the elimination half-life, is reported to be about 2 to 4 hours for the immediate-release capsules. Regulatory data shows that approximately 80% of an administered dose is generally excreted in the urine within 24 hours.

---

Q: Which specific enzyme does Ketoprofen inhibit in the body?

Kelis contains the active ingredient Ketoprofen, which works by inhibiting the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking these enzymes, the medication reduces the synthesis of prostaglandins, which are compounds involved in causing pain and inflammation.

---

Q: Can I crush or chew the extended-release Kelis capsules?

No. The official label instructs that the extended-release capsules must be swallowed whole. These capsules must not be crushed, chewed, broken, or opened, as manipulating them can compromise the extended-release characteristics and may alter how the drug is absorbed.

---

Q: Is there any risk of addiction or dependence with Kelis?

According to regulatory guidance and official documentation, Kelis (Ketoprofen) is not classified as a controlled substance. This classification indicates that the product does not have the same federally monitored risk of abuse or dependence.

---

Q: What is the main chemical class of Kelis?

Kelis (Ketoprofen) belongs to the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAIDs). Its chemical structure is formally identified as (RS)-2-(3-benzoylphenyl)propanoic acid, placing it in a category of medicines designed to reduce pain, fever, and inflammation.

---

Q: Can Kelis be given to pets (e.g., dogs or cats)?

Official human product labels do not provide information or instructions for use in household pets like dogs or cats. While some veterinary-specific formulations of Ketoprofen are approved for use in other animals, the human drug product is intended only for its approved populations as specified in the regulatory labeling.

---

Storage and Disposal Requirements for Kelis (Ketoprofen)

Ketoprofen products must be stored under specific, controlled conditions to maintain stability, as dictated by official labeling.

Storage Conditions

Requirement	Details
Temperature	Store at controlled room temperature (20 C to 25 C).
Protection	Keep in the original container, tightly closed. Protect from moisture and heat. Do not freeze.
Safety	Store out of the sight and reach of children.

Disposal

Unused or expired medicine must not be disposed of in the household trash or down the sink/toilet. Discard outdated medicine via an authorized pharmaceutical take-back program or medicine collection scheme as required by local regulations.